Dr. King Discusses Axillary Node Dissection in Breast Cancer

Tari King, MD, FACS
Published: Tuesday, Feb 13, 2018



Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses axillary node dissection in patients with breast cancer.

Upfront chemotherapy is being used more often, specifically in patients who have known cancer in the lymph nodes, King says. Chemotherapy is being used before surgery in an effort to eradicate the disease in the lymph nodes. Many of these women are offered sentinel node biopsies, but the technique must be adequate in order to determine whether the node is clean.

King says that with the sentinel node procedure, the field is working toward identifying patients with breast cancer who do not need axillary node dissection. King says that patients who start out with clinically evident biopsy-proven nodal disease who receive chemotherapy upfront may require an axillary node dissection.


Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses axillary node dissection in patients with breast cancer.

Upfront chemotherapy is being used more often, specifically in patients who have known cancer in the lymph nodes, King says. Chemotherapy is being used before surgery in an effort to eradicate the disease in the lymph nodes. Many of these women are offered sentinel node biopsies, but the technique must be adequate in order to determine whether the node is clean.

King says that with the sentinel node procedure, the field is working toward identifying patients with breast cancer who do not need axillary node dissection. King says that patients who start out with clinically evident biopsy-proven nodal disease who receive chemotherapy upfront may require an axillary node dissection.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x